Matthias DHuyvetter
Overview
Explore the profile of Matthias DHuyvetter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dewulf J, Massa S, Navarro L, Dekempeneer Y, Santens F, Ceuppens H, et al.
J Nanobiotechnology
. 2024 Dec;
22(1):763.
PMID: 39696571
Background: Folate receptor alpha (FRα) overexpression is seen in many cancers. Radioligand therapy (RLT) has emerged as a promising tool to target FRα and has been investigated previously, but further...
2.
Bocuzzi V, Bridoux J, Pirotte M, Withofs N, Hustinx R, DHuyvetter M, et al.
J Transl Med
. 2024 Dec;
22(1):1113.
PMID: 39695745
No abstract available.
3.
Bocuzzi V, Bridoux J, Pirotte M, Withofs N, Hustinx R, DHuyvetter M, et al.
J Transl Med
. 2024 Nov;
22(1):998.
PMID: 39501292
CD38 is a multifunctional transmembrane glycoprotein found in multiple tissues and overexpressed in many cancer cells, notably in hematological malignancies such as leukemia and multiple myeloma (MM). Therefore, targeting CD38...
4.
Poty S, Ordas L, Dekempeneer Y, Parach A, Navarro L, Santens F, et al.
J Nucl Med
. 2024 Sep;
65(10):1564-1570.
PMID: 39266288
Single-domain antibodies (sdAbs) demonstrate favorable pharmacokinetic profiles for molecular imaging applications. However, their renal excretion and retention are obstacles for applications in targeted radionuclide therapy (TRT). Using a click-chemistry-based pretargeting...
5.
Ceuppens H, Pombo Antunes A, Navarro L, Ertveldt T, Berdal M, Nagachinta S, et al.
Eur J Nucl Med Mol Imaging
. 2024 Sep;
52(2):444-457.
PMID: 39237746
Purpose: Targeted radionuclide therapy (TRT) is a cancer treatment with relative therapeutic efficacy across various cancer types. We studied the therapeutic potential of TRT using fibroblast activation protein-α (FAP) targeting...
6.
Dierick H, Navarro L, Ceuppens H, Ertveldt T, Pombo Antunes A, Keyaerts M, et al.
EJNMMI Radiopharm Chem
. 2024 Jul;
9(1):54.
PMID: 39048805
Background: Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[F]fluorobenzoate ([F]SFB) has shown to be a promising strategy in the development of sdAb-based PET tracers. While automation of the prosthetic group...
7.
Dekempeneer Y, Massa S, Santens F, Navarro L, Berdal M, Lucero M, et al.
J Nucl Med
. 2023 Dec;
64(12):1941-1948.
PMID: 38040444
Fibroblast activation protein α (FAP) is highly expressed on cancer-associated fibroblasts of epithelial-derived cancers. Breast, colon, and pancreatic tumors often show strong desmoplastic reactions, which result in a dominant presence...
8.
Funeh C, Bridoux J, Ertveldt T, De Groof T, Chigoho D, Asiabi P, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242621
The precise delivery of cytotoxic radiation to cancer cells through the combination of a specific targeting vector with a radionuclide for targeted radionuclide therapy (TRT) has proven valuable for cancer...
9.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, et al.
J Nucl Med
. 2023 Apr;
64(5):751-758.
PMID: 37055223
Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (α-TRT) is an intensely investigated treatment approach as the short range of α-particles allows effective treatment of local lesions...
10.
Vargas C, Struelens L, DHuyvetter M, Caveliers V, Covens P
J Nucl Med
. 2022 Oct;
64(3):493-499.
PMID: 36229185
Suborgan absorbed dose estimates in mouse kidneys are crucial to support preclinical nephrotoxicity analyses of α- and β-particle-emitting radioligands exhibiting a heterogeneous activity distribution in the kidneys. This is, however,...